LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences, LLC, an oncology focused, clinical stage biopharmaceutical company, today announced that it will present updates for two of its lead molecules in clinical development at the American Association for Cancer Research (AACR) Annual ...…
News
- Asana BioSciences Announces Presentations of ASN003 (BRAF/PI3K inhibitor) and ASN007 ...
- CytoBioscience CEO: Going public will speed growth
CytoBioscience expects to become a much stronger company with significantly more access to capital once its transformation from being privately owned to publicly traded is complete. I reported last month that the San Antonio-based biotech had essentially acquired, through merger, a subsidiary of…
- A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal
Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal. The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal. Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A…
- Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we ...
Novartis isn't the only big pharma/biotech to be interested in gene and cell therapies. In January, Celgene made a $9 billion bet on Juno Therapeutics, a cancer drugmaker that's working on cell therapies. The deal also drummed up excitement for a possible deal for Bluebird Bio, another company…
- Frontier Airlines launching new SA flights to several destinations
“Raleigh-Durham is an especially important area for research and development,” said Maria Zannes, president and CEO of San Antonio-based bioAffinity Technologies. “North Carolina's universities and medical centers most certainly can be important partners for San Antonio's biotech sector.”.